À la frontière entre plusieurs disciplines scientifiques, la thérapie cellulaire et génique dévoile son plein potentiel pour traiter les maladies incurables et ainsi transformer la vie des patients. Bien que dynamisées par l'élan des opportunités d'investissement, les entreprises biotechnologiques de la région Asie-Pacifique sont confrontées à des défis en termes d'opérations cliniques et d'accès aux marchés.
Join our online webinar and gain an in-depth understanding of the opportunities of cell and gene therapeutic product development and market entry strategies in this fast-evolving industry. Investigate the prospectus of operational excellence, investigator engagement, as well as patient recruitment to accelerate the journey. Additionally, explore Fortrea's solution for navigating the complexity of clinical studies in cell and gene therapy and understand the best practices in supporting the success of both emerging biotech and large pharmaceutical sponsors.
addition to the online presentations, feel free to book a seat at the actual site in Seoul, Korea, to join face-to-face discussions with Fortrea experts and key stakeholders covering the cell and gene therapy ecosystem. Share insights from various facets on advancing CGT clinical development in Asia Pacific.
Learnings
- In-depth insights towards the evolving regulatory framework for cell and gene therapy in the US as well as the major CGT market in APAC regions.
- Navigating the complexity in cell and gene therapy studies, leveraging resources on hospital infrastructure, clinicians, as well as chain logistics to ease the burden of investigators and sites.
- Exploring Fortrea’s dedicated infrastructure and expertise in the CGT arena.
Programme
15:00-15:15 | Landscape & Regulatory
Global CGT landscape and navigating the Regulatory Landscape
Frederick Derosier D.O.
Vice President, Therapeutic Strategy
Clinical Lead for Enterprise Cell and Gene Therapy, Fortrea
Dong Yang
Head of Regulatory China, Fortrea
15:15-15:30 | Insights from sites
Addressing the Complexities of Conducting CGT clinical trials
Jennifer Hollands, Ph. D.
Government and Academic Liaison, Cell Therapies
15:30-15:45 | Commercialization
Advancing cutting-edge therapies from bench-to-bedside
Eytan Abraham
Vice President, Business head of Cell, Gene and Nucleic Acids franchises, Resilience
15:45-16:00 | Operation Excellence
From Benchtop to Patient -Manufacturing Considerations for Clinical Development of Advanced Therapeutics
Ritu Singla
Project Manager, Fortrea
16:00-16:30 | Panel Discussion
Advancing CGT trial ecosystem in APAC
